Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats

Journal of Neural Transmission

Volumn 115, Issue 8, 2008, Pages 1133-1139

  Marin, C ^a,b,c   Aguilar, E ^a,c   Bonastre, M ^a,c  

^a Laboratori de Neurologia Experimental   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

6 Hydroxydopamine; Levodopa; Locus coeruleus; Motor fluctuations; Parkinson's disease

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; BENSERAZIDE; DOPAMINE TRANSPORTER; LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOSE TIME EFFECT RELATION; LOCUS CERULEUS; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR DYSFUNCTION; NONHUMAN; NORADRENERGIC NERVE; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; ZONA COMPACTA;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DENERVATION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HYDROXYDOPAMINES; IMMUNOHISTOCHEMISTRY; LEVODOPA; LOCUS COERULEUS; MALE; MOVEMENT; NEOSTRIATUM; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 49749111104     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-008-0060-5     Document Type: Article

References (53)

1. N Anden M Grabowska 1976 Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain Eur J Pharmacol 39 275 282
2. T Archer SO Ogren G Johansson SB Ross 1982 DSP-4 induced two-active avoidance impairment in rats: involvement of central and not peripheral noradrenaline depletion Psychopharmacology 76 303 309
3. T Archer A Fredriksson 2000 Effects of clonidine and alpha-adrenoreceptor antagonists on motor activity in DSP-4 treated mice: dose-, time- and parameter-dependency Neurotox Res 4 235 247
4. P Belujon E Bezard A Taupignon B Bioulac A Benazzouz 2007 Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats J Neurosci 27 9595 9606
5. G Bing Y Zhang T Watanabe BS McEven EA Stone 1994 Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra Brain Res 668 161 165
6. NS Canteras SJ Shammah-Lagnado BA Silva JA Ricardo 1990 Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat Brain Res 513 43 59
7. P Chopin FC Colpaert M Marien 1999 Effects of alpha-2 adrenoreceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway J Pharmacol Exp Ther 288 798 804
8. GL Collingridge TA James 1979 Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra J Physiol 290 44
9. MR DeLong 1990 Primate models of movement disorders of basal ganglia origin Trends Neurosci 13 281 285
10. K Del Tredici U Rüb RA De Vos JR Bohl H Braak 2002 Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61 413 426
11. H Ehringer O Hornykiewicz 1960 Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system Klin Wochenschr 38 1236 1239
12. TM Engber SM Papa RC Boldry TN Chase 1994 NMDA receptor blockade reverses motor response alterations induced by levodopa Neuroreport 5 2586 2588
13. F Fornai L Bassi MT Torracca V Scalori GU Corsini 1995 Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice Eur J Pharmacol 283 99 102
14. F Fornai L Bassi MT Torracca MG Alessandri V Scalori GU Corsini 1996 Region-and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents Neurodegeneration 5 241 249
15. F Fornai MG Alessandri MT Torracca L Bassi GU Corsini 1997 Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletion J Pharmacol Exp Ther 283 100 107
16. F Fornai AB di Poggio A Pellegrini S Ruggieri A Paprelli 2007 Noradrenaline in Parinson's disease progression to current therapeutics Curr Med Chem 14 1330 1334
17. LS Forno 1996 Neuropathology of Parkinson's disease J Neuropathol Exp Neurol 55 259 272
18. JM Fritschy R Grzanna 1989 Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals Neuroscience 30 191 197
19. M Gesi P Soldani FS Giorgi A Santiami I Bonaccorsi F Fornai 2000 The role of the locus coeruleus in the development of Parkinson's disease Neurosci Biobehav Rev 24 655 668
20. J Grenhoff M Nisell S Ferré G Aston-Jones TH Svensson 1993 Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat J Neural Transm Gen Sect 93 11 25
21. O Hornykiewicz SJ Kish 1987 Biochemical pathophysiology of Parkinson's disease Adv Neurol 45 19 34
22. Hornykiewicz O, Pifl C (1994) The validity of the MPTP primate model from neurochemical pathology of idiopathic Parkinson's disease. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson's disease. CRC Press, Boca Raton, pp 59-71
23. AL Hudson ES Robinson MD Lalies RJ Tyacke HC Jackson DJ Nutt 1999 In vitro and in vivo approaches to the characterization of the alpha2- adrenoreceptor J Auton Pharmacol 19 311 320
24. BE Jones RY Moore 1977 Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study Brain Res 127 25 53
25. BE Jones RY Yang 1985 The afferent projections from the reticular formation and the locus coeruleus studied by anterograde and retrograde axonal transport in the rat J Comp Neurol 242 56 92
26. T Kitada S Asakawa N Hattori H Matsumune Y Yamamura S Minoshima M Yokochi Y Mizuno N Shimizu 1998 Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism Nature 392 605 608
27. VS Kostic J Marinkovic M Svetel E Stefanova S Przedborski 2002 The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications Eur J Neurol 9 9 14
28. AJ Lategan MR Marien FC Coalpaert 1990 Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis Brain Res 523 134 138
29. AJ Lategan MR Marien FC Colpaert 1992 Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study Life Sci 50 995 999
30. M Marien M Briley E Colpaert 1993 Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice Eur J Pharmacol 236 487 489
31. Marien M, Lategan A, Colpaert F (1994) Noradrenergic control of striatal dopamine. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson's disease. CRC Press, Boca Raton, pp 127-138
32. MR Marien FC Colpaert AC Rosenquist 2004 Noradrenergic mechanisms in neurodegenerative diseases: a theory Brain Res Rev 45 38 78
33. ST Mason HC Fibiger 1979 Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase J Comp Neurol 187 703 724
34. M Mavridis AD Degryse AJ Lategan MR Marien FC Colapert 1991 Effect of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease Neuroscience 41 507 523
35. H Narabayashi 1983 Pharmacological basis of akinesia in Parkinson's disease J Neural Transm Suppl 19 143 151
36. K Nishi T Kondo H Narabayashi 1991 Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by l-Dopa Neurosci Lett 123 244 247
37. JG Nutt NH Holford 1996 The response to levodopa in Parkinson's disease imposing pharmacological law and order Ann Neurol 39 561 573
38. Nutt DJ, Lalies M, Hudson A (1994) The effects of alpha-2-adrenoreceptor antagonists on extracellular dopamine concentrations in the rat striatum. In: Colpaert F, Briley M (eds) Noradrenergic mechanisms in Parkinson's disease. Academic Press, New York, pp 159-172
39. JA Obeso CW Olanow JG Nutt 2000 Levodopa motor complications in Parkinson's disease Trends Neurosci 23 10 Suppl S8 S19
40. JA Obeso MC Rodríguez-Oroz C Marin F Alonso I Zamarbide JL Lanciego M Rodríguez-Díaz 2004 The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits Neurology 62 1 Suppl 1 S17 S30
41. CW Olanow JA Obeso F Stocchi 2006 Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications Lancet Neurol 5 677 687
42. SM Papa TM Engber AM Kask TN Chase 1994 Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration Brain Res 662 69 74
43. A Parent LN Hazrati 1995 Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry Brain Res Brain Res Rev 20 128 154
44. Paxinos G, Watson C. (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
45. V Pérez V Sosti A Rubio M Barbanoj J Rodríguez- Álvarez J Kulisevsky 2007 Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration Eur J Pharmacol 576 83 90
46. C Pifl G Schingnitz O Hornykiewicz 1991 Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey Neuroscience 44 591 605
47. KS Rommelfanger D Weinshenker 2007 Norepimephrine: the redheaded stepchild of Parkinson's disease Biochem Pharmacol 74 177 190
48. KS Rommelfanger GL Edwards KG Freeman LC Liles GW Miller D Weinshenker 2007 Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice Proc Natl Acad Sci USA 104 13804 13809
49. J Srinivasan WJ Schmidt 2003 Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats Eur J Neurosci 17 2586 2592
50. J Srinivasan WJ Schmidt 2004 Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats J Neural Transm 111 13 26
51. B Thomas R von Coelln AS Mandir DB Trinkaus MH Farah KL Lim NY Calingasan MF Beal VL Dawson TM Dawson 2007 MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity Neurobiol Dis 26 312 322
52. C Zarow SA Lyness JA Mortimer HC Chui 2007 Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson's disease Arch Neurol 60 337 341
53. Y Zhang J Gao KK Chung H Huang VL Dawson TM Dawson 2000 Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synpatic vesicle-associated protein, CDCrel-1 Proc Natl Acad Sci USA 97 13354 13359